Latest Breaking News On - Active lupus - Page 1 : comparemela.com

Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023

Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoSan diegoErnie yapSamir parikhMatt bakerLucy hodgeBo wenHenry leherMatt trumanGabriel contrerasRobertb huizingaKory engelkeChristopher collinsKrishani kumari rajanayakeSalem almaani

Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023

Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoSan franciscoMatt trumanVanessa birardiKory engelkeEmily littlejohnEstela puchulu campanellaDuxin sunChristopher collinsGabriel contrerasMatt bakerAnkhbayar lkhagvaArnon araziKrishani kumari rajanayakeSimon zhou

Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations

Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomNeil solomonsHans joachim andersDana lynchEuropean congressAurinia pharmaceuticals incAmerican college of rheumatologyEuropean alliance of associationsUniversity of munichCorporate communicationsAurinia pharmaceuticalsEuropean renal associationEuropean allianceChief medical officerAmerican college

Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress

Press release content from Business Wire. The AP news staff was not involved in its creation.

United statesUnited kingdomFrance generalNeil solomonsAnca askanaseYk onno tengDana lynchAurinia pharmaceuticals incColumbia university medical centerAmerican college of rheumatologyLeiden university medical centerCorporate communicationsAurinia pharmaceuticalsEuropean renal associationChief medical officerAmerican college

Aurinia Pharmaceuticals Inc : Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress

Use of LUPKYNIS was safe and well tolerated in patients for up to three years of treatment, with no new safety signals In AURORA 2, long-term treatment with LUPKYNIS led to a clinically relevant

United statesUnited kingdomFrance generalNeil solomonsAnca askanaseYk onno tengDana lynchAurinia pharmaceuticals incColumbia university medical centerAmerican college of rheumatologyLeiden university medical centerCorporate communicationsAurinia pharmaceuticalsEuropean renal associationChief medical officerAmerican college